Identification of serum metabolic markers in non-obese hypertensive patients using non-targeted metabolomics

作者：Yifan Xu, Yilin Jiang, Jia Liang Lu, Xu Chen, Qing Li, Hongjun Zhu · 发表于：Scientific Reports · 年份：2025 · DOI：10.1038/s41598-025-02162-0 · 被引用次数：3 · 研究领域：Diet and metabolism studies、Metabolomics and Mass Spectrometry Studies、Nutritional Studies and Diet

The future of hypertension management lies in distinguishing disease subtypes for precise control. The underlying drivers and pathology of non-obese hypertension (J-HTN) remain unclear. There is a lack of biomarkers for the early identification of J-HTN. The aim of this study was to identify circulating metabolomic profiles that facilitate the early detection of J-HTN patients, thereby providing valuable insights for more targeted and precision-based therapies. A non-targeted metabolomics approach was used to quantify serum metabolites in 120 patients with newly diagnosed hypertension, and to determine the metabolomic characteristics of J-HTN and two types of obese hypertension (fat-dominant and muscle-dominant). 4 metabolites unique to J-HTN were identified, with lysophosphatidylcholine 22:6 (LysoPC(22:6/0:0)) standing out as the marker showing the most pronounced difference. Using the serum metabolome alone, we were able to distinguish J-HTN from other hypertensive patients. In a secondary validation with an independent cohort of 60 medically treated J-HTN patients, 3 metabolites, including LysoPC(22:6/0:0), remained significantly altered. The serum metabolic profiles identified in this study enable the early detection of J-HTN, with LysoPC(22:6/0:0) emerging as a highly promising biomarker. This metabolite may also correlate with the clinical efficacy of J-HTN treatments.